» Articles » PMID: 24672242

Therapeutic Interventions to Reduce the Risk of Progression from Prediabetes to Type 2 Diabetes Mellitus

Overview
Publisher Dove Medical Press
Date 2014 Mar 28
PMID 24672242
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Clinical trials have demonstrated that it is possible to prevent diabetes through lifestyle modification, pharmacological intervention, and surgery. This review aims to summarize the effectiveness of these various therapeutic interventions in reducing the risk of progression of prediabetes to diabetes, and address the challenges to implement a diabetes prevention program at a community level. Strategies focusing on intensive lifestyle changes are not only efficient but cost-effective and/or cost-saving. Indeed, lifestyle intervention in people at high risk for type 2 diabetes mellitus (T2DM) has been successful in achieving sustained behavioral changes and a reduction in diabetes incidence even after the counseling is stopped. Although prediabetes is associated with health and economic burdens, it has not been adequately addressed by interventions or regulatory agencies in terms of prevention or disease management. Lifestyle intervention strategies to prevent T2DM should be distinct for different populations around the globe and should emphasize sex, age, ethnicity, and cultural and geographical considerations to be feasible and to promote better compliance. The translation of diabetes prevention research at a population level, especially finding the most effective methods of preventing T2DM in various societies and cultural settings remains challenging, but must be accomplished to stop this worldwide epidemic.

Citing Articles

Enhancements in Parkinson's Disease Management: Leveraging Levodopa Optimization and Surgical Breakthroughs.

Sharma R, Kour A, Dewangan H Curr Drug Targets. 2024; 26(1):17-32.

PMID: 39350551 DOI: 10.2174/0113894501319817240919103802.


The association of platelet to white blood cell ratio with diabetes: a nationwide survey in China.

Liu F, Wang T, Wang S, Zhao X, Hua Y Front Endocrinol (Lausanne). 2024; 15:1418583.

PMID: 38957446 PMC: 11217324. DOI: 10.3389/fendo.2024.1418583.


Associations of obesity-related indices with prediabetes regression to normoglycemia among Chinese middle-aged and older adults: a prospective study.

Yang H, Zhang M, Nie J, Zhang M, Lu G, Chen R Front Nutr. 2023; 10:1075225.

PMID: 37275653 PMC: 10235473. DOI: 10.3389/fnut.2023.1075225.


The suitability, acceptability, and feasibility of a culturally contextualized low-calorie diet among women at high risk for diabetes mellitus in Kerala: a mixed-methods study.

Kodapally B, Vilane Z, Nsamba J, Joseph A, Mathews E, Thankappan K Int J Diabetes Dev Ctries. 2022; :1-16.

PMID: 36245572 PMC: 9552705. DOI: 10.1007/s13410-022-01134-8.


Characterizing epidemiology of prediabetes, diabetes, and hypertension in Qataris: A cross-sectional study.

Al-Thani M, Al-Mutawa K, Alyafei S, A Ijaz M, A H Khalifa S, B Kokku S PLoS One. 2021; 16(10):e0259152.

PMID: 34699571 PMC: 8547702. DOI: 10.1371/journal.pone.0259152.


References
1.
Schweizer A, Couturier A, Foley J, Dejager S . Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes. Diabet Med. 2007; 24(9):955-61. DOI: 10.1111/j.1464-5491.2007.02191.x. View

2.
Qi L, Hu F, Hu G . Genes, environment, and interactions in prevention of type 2 diabetes: a focus on physical activity and lifestyle changes. Curr Mol Med. 2008; 8(6):519-32. DOI: 10.2174/156652408785747915. View

3.
Saaristo T, Moilanen L, Korpi-Hyovalti E, Vanhala M, Saltevo J, Niskanen L . Lifestyle intervention for prevention of type 2 diabetes in primary health care: one-year follow-up of the Finnish National Diabetes Prevention Program (FIN-D2D). Diabetes Care. 2010; 33(10):2146-51. PMC: 2945150. DOI: 10.2337/dc10-0410. View

4.
Vella A, Bock G, Giesler P, Burton D, Serra D, Ligueros Saylan M . Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes. 2007; 56(5):1475-80. DOI: 10.2337/db07-0136. View

5.
Chiasson J, Josse R, Gomis R, Hanefeld M, Karasik A, Laakso M . Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003; 290(4):486-94. DOI: 10.1001/jama.290.4.486. View